
Is an innovative screening, diagnosis and monitoring tool for a
COMPLETE
LIVER EVALUATION
and primary liver cancer prevention

Fibronostics Secures Financing,
announces new CEO

LIVERFASt™
for NAFLD, NASH,
HCV, HBV, Cirrhosis.

Help quantify and monitor liver damage in subjects with metabolic risk and fatty liver as well with viral hepatitis.
